Hologic's Panther Fusion Signals More Molecular Diagnostics Upside
HOLX's Panther Fusion expands its diagnostics menu, fueling assay growth and unlocking more upside in molecular testing.
The Role of M&A in Hologic's Growth Story: Are More Deals in Sight?
HOLX fuels growth with targeted M&A across Diagnostics, Breast Health, and GYN Surgical, backed by a strong balance sheet.
Seeking Clues to Hologic (HOLX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for som...
Hologic Q3 Preview: Tariff Pressure And Undervalued Stock Price, Initiate With Buy
I am initiating a Buy rating on Hologic, Inc. with a fair value of $81, as current risks are priced in. Hologic's strong diagnostic portfolio, recurring consumables revenue, and expanding assay men...
How Hologic Leverages Its Financial Firepower to Drive Long-Term Value
Backed by robust profitability, HOLX deploys billions into acquisitions and repurchases to boost future earnings.
Hologic (HOLX) Suffers a Larger Drop Than the General Market: Key Insights
Hologic (HOLX) concluded the recent trading session at $64.14, signifying a -1.6% move from its prior day's close.
Hologic reportedly rejects $16B go-private offer from TPG, Blackstone
TPG and Blackstone Inc (NYSE:BX), two private equity firms, have made a non-binding offer of more than $16 billion to take medical equipment-maker Hologic Inc (NASDAQ:HOLX) private, according to a ...
Insights Into Hologic (HOLX) Q2: Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for s...
GYN Surgical Division Likely to Drive Hologic's Q2 Earnings
HOLX's second-quarter fiscal 2025 performance is likely to have benefited from expanding breast health offerings.
Cellulite Treatment Market Trends, Growth Opportunities and Shares 2025-2030; Featuring Key Players - Hologic (Cynosure), Merz Pharma, Syneron Medi...
Dublin, April 25, 2025 (GLOBE NEWSWIRE) -- The "Cellulite Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets....
Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #cemark--Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software.
Two S&P 500 hidden gems to buy right now
Although the benchmark S&P 500's biggest names tend to dominate investor attention, the index also features lesser-known stocks with significant growth potential.
Here's Why Hologic (HOLX) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Hologic (HOLX) Q1 Earnings Surpass Estimates
Hologic (HOLX) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $0.98 per share a year ago.
Breast Health Performance Likely to Aid Hologic's Q1 Earnings
In the first quarter of fiscal 2025, HOLX is expected to have benefited from expanding breast health offerings.
Related Companies